These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20425392)

  • 21. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Momelotinib for the treatment of myelofibrosis with anemia.
    Tremblay D; Mesa R
    Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.
    Verstovsek S
    Clin Cancer Res; 2010 Apr; 16(7):1988-96. PubMed ID: 20215535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
    Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
    Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
    Mascarenhas J
    Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The new landscape of therapy for myelofibrosis.
    Gowin K; Emanuel R; Geyer H; Mesa RA
    Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory agents in myelofibrosis.
    Tabarroki A; Tiu RV
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
    Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
    Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond JAK inhibitor therapy in myelofibrosis.
    Odenike O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alleviating anemia and thrombocytopenia in myelofibrosis patients.
    Cervantes F; Correa JG; Hernandez-Boluda JC
    Expert Rev Hematol; 2016 May; 9(5):489-96. PubMed ID: 26891375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
    El Fakih R; Popat U
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
    Sastow D; Mascarenhas J; Tremblay D
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for combination therapy in myelofibrosis.
    Mascarenhas J
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2 inhibitors: A reality? A hope?
    Apostolidou E; Kantarjian HM; Verstovsek S
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S340-5. PubMed ID: 19778862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
    Barba P; Fox ML; Blanco A; Valcárcel D
    Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
    [No Abstract]   [Full Text] [Related]  

  • 37. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
    Winton EF; Kota V
    Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing patients with myelofibrosis and low platelet counts.
    Al-Ali HK; Vannucchi AM
    Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental therapy in myelofibrosis with myeloid metaplasia.
    Verstovsek S; Quintás-Cardama A; Kantarjian H; Tefferi A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1555-63. PubMed ID: 17107281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.